All In Biotech

Drug Trial Radar · NCT06787586

Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Part, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and PK of ATTO1310 in Adult Volunteers, Patients With Atopic Dermatitis, and Patients With Chronic Pruritus

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 108 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

108

Actual

Start

Jan 14, 2025

Primary completion

Jun 11, 2026

Study completion Jun 11, 2026

Sponsor

Lead sponsor
Attovia Therapeutics IncIndustry
Sponsor type
Industry
First posted
Jan 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-1310 in healthy adults, patients with atopic dermatitis and patients with chronic pruritus. The main questions it aims to answer are: What medical problems do participants have when taking ATTO-1310? How long does ATTO-1310 stay in the body after dosing? Researchers will compare ATTO-1310 to a placebo (a look-alike substance that contains no drug). Participants will be dosed with ATTO-1310 or a placebo, visit the clinic for checkups and tests, and keep a diary of their symptoms.

Conditions

  • Normal Volunteers
  • Atopic Dermatitis (AD)
  • Atopic Eczema
  • Chronic Pruritus

Interventions

  • ATTO-1310Drug

    ATTO-1310 Attobody

  • ATTO-1310 PlaceboDrug

    Placebo preparation to match ATTO-1310 Dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of AEsTime frame: 0-113 Days for SAD; 0-143 Days for MAD
  2. Incidence of laboratory abnormalitiesTime frame: 0-113 Days for SAD; 0-143 Days for MAD
  3. Incidence of ECG abnormalitiesTime frame: 0-113 Days for SAD; 0-143 Days for MAD
  4. Incidence of vital sign abnormalitiesTime frame: 0-113 Days for SAD; 0-143 Days for MAD

Locations

17 sites in 2 countries. Site status is shown where the registry gives one.

  • Attovia Clinical Site 103

    Encinitas, California

  • Attovia Clinical Site 116

    Rocklin, California

  • Attovia Clinical Site 107

    Sacramento, California

  • Attovia Clinical Site 109

    Coral Gables, Florida

  • Attovia Clinical Site 118

    Margate, Florida

  • Attovia Clinical Site 102

    Plainfield, Indiana

  • Attovia Clinical Site 104

    Saint Joseph, Missouri

  • Attovia Clinical Site 106

    Reno, Nevada

  • Attovia Clinical Site 114

    New York, New York

  • Attovia Clinical Site 119

    New York, New York

  • Attovia Clinical Site 108

    San Antonio, Texas

  • Attovia Clinical Site 110

    Fredericton, New Brunswick, Canada

  • Attovia Clinical Site 111

    Newmarket, Ontario, Canada

  • Attovia Clinical Site 112

    Peterborough, Ontario, Canada

  • Attovia Clinical Site 113

    Toronto, Ontario, Canada

  • Attovia Clinical Site 105

    Montreal, Quebec, Canada

  • Altasciences

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.